A novel dermorphin tetrapeptide analog produced analgesia partly through triggering endogenous opioid peptide release, confirming the drug-endogenous peptide amplification principle for enhanced pain relief.
Key findingAmidino-TAPA, a novel dermorphin tetrapeptide analog, produced antinociception partly mediated by endogenous opioid peptide release (confirmed by anti
What the researchers found
Amidino-TAPA, a novel dermorphin tetrapeptide analog, produced antinociception partly mediated by endogenous opioid peptide release (confirmed by antiserum blocking), extending the drug-endogenous amplification mechanism to a new opioid drug class.
Why it matters
Relevant for opioid-peptides, pain, peptide-design.
How the study worked
animal-study study on opioid-peptides, pain.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.
European journal of pharmacology, 560(2-3), 150-9
Citation
Mizoguchi, Hirokazu; Watanabe, Chizuko; Watanabe, Hiroyuki; Moriyama, Kaori; Sato, Bunsei; Ohwada, Keiko; Yonezawa, Akihiko; Sakurada, Tsukasa; Sakurada, Shinobu. (2007). Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.. European journal of pharmacology, 560(2-3), 150-9.